Country Club Trust Company n.a. increased its stake in Merck & Co. (NYSE:MRK) by 4.0% during the second quarter, according to its most recent filing with the Securities and Exchange Commission (SEC). The fund owned 134,265 shares of the company’s stock after buying an additional 5,202 shares during the period. Merck & Co. accounts for approximately 1.1% of Country Club Trust Company n.a.’s holdings, making the stock its 26th largest position. Country Club Trust Company n.a.’s holdings in Merck & Co. were worth $7,735,000 at the end of the most recent reporting period.
Other large investors also recently modified their holdings of the company. Burke & Herbert Bank & Trust Co. raised its stake in shares of Merck & Co. by 4.3% in the first quarter. Burke & Herbert Bank & Trust Co. now owns 25,862 shares of the company’s stock valued at $1,368,000 after buying an additional 1,059 shares in the last quarter. Alpha Windward LLC raised its stake in shares of Merck & Co. by 0.9% in the first quarter. Alpha Windward LLC now owns 4,941 shares of the company’s stock valued at $261,000 after buying an additional 42 shares in the last quarter. Capital Investment Advisors LLC raised its stake in shares of Merck & Co. by 12.4% in the first quarter. Capital Investment Advisors LLC now owns 48,868 shares of the company’s stock valued at $2,586,000 after buying an additional 5,386 shares in the last quarter. Mission Wealth Management LLC raised its stake in shares of Merck & Co. by 176.0% in the first quarter. Mission Wealth Management LLC now owns 46,333 shares of the company’s stock valued at $2,451,000 after buying an additional 29,543 shares in the last quarter. Finally, Iberiabank Corp raised its stake in shares of Merck & Co. by 6.7% in the first quarter. Iberiabank Corp now owns 84,035 shares of the company’s stock valued at $4,446,000 after buying an additional 5,308 shares in the last quarter. 72.93% of the stock is currently owned by hedge funds and other institutional investors.
Shares of Merck & Co. (NYSE:MRK) traded up 0.81% during midday trading on Friday, hitting $62.41. The stock had a trading volume of 13,605,282 shares. Merck & Co. has a one year low of $47.97 and a one year high of $64.00. The company has a market capitalization of $172.58 billion, a PE ratio of 34.23 and a beta of 0.63. The firm’s 50-day moving average is $62.76 and its 200 day moving average is $58.03.
Merck & Co. (NYSE:MRK) last released its quarterly earnings data on Friday, July 29th. The company reported $0.93 EPS for the quarter, beating analysts’ consensus estimates of $0.91 by $0.02. The business earned $9.84 billion during the quarter, compared to the consensus estimate of $9.79 billion. Merck & Co. had a return on equity of 23.41% and a net margin of 13.01%. The firm’s revenue was up .6% on a year-over-year basis. During the same quarter in the prior year, the company posted $0.86 earnings per share. Equities analysts expect that Merck & Co. will post $3.75 earnings per share for the current fiscal year.
The business also recently disclosed a quarterly dividend, which will be paid on Friday, October 7th. Investors of record on Thursday, September 15th will be issued a $0.46 dividend. The ex-dividend date of this dividend is Tuesday, September 13th. This represents a $1.84 dividend on an annualized basis and a yield of 2.95%. Merck & Co.’s dividend payout ratio is presently 101.10%.
MRK has been the topic of a number of research analyst reports. Goldman Sachs Group Inc. reissued a “neutral” rating and set a $60.00 price target on shares of Merck & Co. in a report on Wednesday, June 8th. Argus reissued a “buy” rating on shares of Merck & Co. in a report on Thursday, June 9th. Jefferies Group lowered their price target on Merck & Co. from $54.00 to $53.00 and set a “hold” rating on the stock in a report on Tuesday, June 14th. BMO Capital Markets reissued an “outperform” rating and set a $62.00 price target on shares of Merck & Co. in a report on Tuesday, June 28th. Finally, Vetr raised Merck & Co. from a “sell” rating to a “buy” rating and set a $62.26 price target on the stock in a report on Monday, July 4th. One equities research analyst has rated the stock with a sell rating, twelve have issued a hold rating and nine have assigned a buy rating to the company. Merck & Co. has a consensus rating of “Hold” and a consensus target price of €63.20 ($70.23).
In related news, EVP Clark Golestani sold 3,000 shares of the company’s stock in a transaction dated Wednesday, August 10th. The stock was sold at an average price of €63.03 ($70.03), for a total value of €189,090.00 ($210,100.00). The transaction was disclosed in a filing with the Securities & Exchange Commission, which is available at this link. Also, Chairman Kenneth C. Frazier sold 392,000 shares of the company’s stock in a transaction dated Friday, August 5th. The shares were sold at an average price of €61.81 ($68.68), for a total value of €24,229,520.00 ($26,921,688.89). Following the completion of the sale, the chairman now owns 760,877 shares of the company’s stock, valued at approximately €47,029,807.37 ($52,255,341.52). The disclosure for this sale can be found here. 0.05% of the stock is owned by corporate insiders.
Merck & Co. Company Profile
Merck & Co, Inc is a global healthcare company. The Company offers health solutions through its prescription medicines, vaccines, biologic therapies and animal health products, which it markets directly and through its joint ventures. It operates through one segment, Pharmaceutical. The Company’s Pharmaceutical segment includes human health pharmaceutical and vaccine products marketed either directly by the Company or through joint ventures.
Want to see what other hedge funds are holding MRK? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Merck & Co. (NYSE:MRK).
Receive News & Ratings for Merck & Co. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Merck & Co. and related companies with MarketBeat.com's FREE daily email newsletter.